Phase I study on suberoylanilide hydroxyamic acid (vorinostat) a histone deacetylase inhibitor, in palliative radiotherapy for advanced tumors

Trial Profile

Phase I study on suberoylanilide hydroxyamic acid (vorinostat) a histone deacetylase inhibitor, in palliative radiotherapy for advanced tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Pelvic cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms PRAVO
  • Most Recent Events

    • 23 Oct 2013 Gene expression analysis presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 06 Apr 2010 Results have been published online in the Lancet Oncology.
    • 22 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top